Literature DB >> 12410646

First-time development of FVIII inhibitor in haemophilia patients during the postoperative period.

K Ghosh1, F Jijina, S Shetty, M Madkaikar, D Mohanty.   

Abstract

Development of inhibitor to FVIII in haemophilia patients is well-known and is not uncommon. However, their development for the first time during the postoperative period has hardly been reported. In a developing country such as India, where resources are limited, development of such an eventuality may prove disastrous. However, as many of our patients are sparingly treated, therefore, even if they test negative for the inhibitor preoperatively, they may get the requisite FVIII antigenic stimulation during the preoperative and immediate postoperative period, leading to the development of inhibitors during this critical time of wound healing. We describe here six patients who developed such an inhibitor, from a group of 35 patients with haemophilia A who underwent various surgical procedures (19%). We stress that such an eventuality may not remain rare in developing countries as more patients of severe haemophilia undergo surgery and are therefore challenged for the first time in their life with large amounts of FVIII concentrate during their preoperative period.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12410646     DOI: 10.1046/j.1365-2516.2002.00687.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  6 in total

1.  Haematology research in India: past, present and future.

Authors:  Kanjaksha Ghosh
Journal:  Indian J Hematol Blood Transfus       Date:  2011-05-08       Impact factor: 0.900

2.  The Epidemiology of FVIII Inhibitors in Indian Haemophilia A Patients.

Authors:  Patricia Pinto; Tejashree Shelar; Vidhya Nawadkar; Darshana Mirgal; Alfiya Mukaddam; Preethi Nair; Priyanka Kasatkar; Tejasvita Gaikwad; Shahnaz Ali; Anshul Jadli; Rucha Patil; Anita Parihar; Sharda Shanbhag; Bipin Kulkarni; Kanjaksha Ghosh; Shrimati Shetty
Journal:  Indian J Hematol Blood Transfus       Date:  2014-02-05       Impact factor: 0.900

Review 3.  Immune response to FVIII in hemophilia A: an overview of risk factors.

Authors:  Kanjaksha Ghosh; Shrimati Shetty
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

4.  Management of Haemophilia in Developing Countries: Challenges and Options.

Authors:  Kanjaksha Ghosh; Kinjalka Ghosh
Journal:  Indian J Hematol Blood Transfus       Date:  2015-06-18       Impact factor: 0.900

5.  Hemophilia care in India: a review and experience from a tertiary care centre in uttar pradesh.

Authors:  Shubha Phadke
Journal:  Indian J Hematol Blood Transfus       Date:  2011-07-12       Impact factor: 0.900

6.  A case report on the surgical treatment of the huge inflammatory pseudotumor in the AIDS patient with hemophilic.

Authors:  Baochi Liu; Li Liu; Yanling Feng; Lei Li
Journal:  Case Rep Pathol       Date:  2011-09-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.